Back to search

Article

Cilta-cel salvages ide-cel failure in relapsed multiple myeloma by driving distinct immune responses

2025-07-11

Abstract excerpt

<h4>ABSTRACT</h4> Ide-cel and cilta-cel are the two FDA-approved anti-BCMA CAR T cell therapies for the treatment of relapsed/refractory multiple myeloma. Here, we studied a patient who was initially treated with ide-cel with progressive disease and subsequently treated with cilta-cel with a complete response. To elucidate the underlying mechanisms underpinning the distinct clinical outcomes, we conducted multimo...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0d57bb7f-236a-5474-9a02-88f89d5ea656
DOI
10.1101/2025.07.10.25331322
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Cilta-cel salvages ide-cel failure in relapsed multiple myeloma by driving distinct immune responsesDOI 10.1101/2025.07.10.25331322
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myelomaSemantic proximity
Single-Cell Analysis Reveals Ide-cel and Cilta-cel Characteristics That Influence EfficacySemantic proximity
Strategies for Salvage Therapy Post CAR-T Therapy Failure in Refractory/Relapsed Multiple Myeloma PatientsSemantic proximity
Rational engineering of sdAb-based CAR T cells targeting BCMA enhances antitumor efficacy and persistence in Multiple MyelomaSemantic proximity
Outcomes of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma by Race: A Multicenter Real-World StudySemantic proximity
BCMA/CD19 dual-targeting with FasTCAR: AZD0120 demonstrates potent preclinical efficacy in multiple myelomaSemantic proximity
CAR T-cell therapy in multiple myeloma: mission accomplished?Semantic proximity
Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meetingSemantic proximity
The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patientsSemantic proximity
Longitudinal multi-omic profiling uncovers immune escape and predictors of response in multiple myelomaSemantic proximity
Single-Cell Multiomics Reveals Regulatory Mechanisms of CAR T Cell Persistence and Dysfunction in Multiple MyelomaSemantic proximity
Robust CD4 <sup>+</sup> CAR T cell Expansion Is Associated with Non-ICANS Neurotoxicities Following Ciltacabtagene AutoleucelSemantic proximity
Select a neighboring publication to make it the new centre.